bevacizumab,atezolizumab
roche
['hcc', ' bev ']
agree option for high risk rhcc but what s the benefit of additional bev - do we need? will be exciting year as other adjuvant trials read out! and more neoadjuvant data to come #aacr23 
Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own 🇮🇪🇨🇦